P. Roy Vagelos, MD |
Chairman of the Board |
P. Roy Vagelos, MD, has been Chairman of the Board of the Company since January 1995. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief
Executive Officer of Merck & Co., Inc. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985, and Chairman in 1986. Dr.
Vagelos retired from all positions with Merck in 1994. Dr. Vagelos is the Chairman of the Board of Theravance, Inc.
Leonard S. Schleifer, MD, PhD |
President and Chief Executive Officer |
Leonard S. Schleifer, MD, PhD, founded the Company in 1988,
has been a Director and its President and Chief Executive Officer since its inception, and served as Chairman of the Board from 1990 through 1994.
In 1992, Dr. Schleifer was appointed Clinical Professor of Neurology at Cornell University Medical College (now called Weill Medical College
of Cornell University), and from 1984 to 1988 he was Assistant Professor at Cornell University Medical College in the Departments of
Neurology and Neurobiology. Dr. Schleifer received his MD and PhD in Pharmacology from the University of Virginia. Dr. Schleifer is a
licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology.
George D. Yancopoulos, MD, PhD |
Executive Vice President, Chief Scientific Officer and President,
Regeneron Research Laboratories |
George D. Yancopoulos, MD, PhD, has been Executive
Vice President, Chief Scientific Officer and President, Regeneron Research Laboratories since December 2000 and a Director since 2001.
Prior to that date, he was Senior Vice President, Research, a position he held since June 1997, and Chief Scientific Officer, a position
he held since January 1998. Dr. Yancopoulos was Vice President Discovery from January 1992 until June 1997, Head of Discovery from January
1991 to January 1992, and Senior Staff Scientist from March 1989 to January 1991. He received his PhD in Biochemistry and Molecular
Biophysics and his MD from Columbia University. Dr. Yancopoulos is a member of the National Academy of Sciences.
Charles A. Baker |
Retired Chairman of the Board, President and Chief Executive Officer
of The Liposome Company, Inc. |
Charles A. Baker has been a Director of the Company since February 1989. In September 2000, Mr. Baker retired as Chairman, President, and Chief Executive Officer of
The Liposome Company, Inc., a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various pharmaceutical
companies, including tenures as Group Vice President, Squibb Corporation (now Bristol-Myers Squibb) and President, Squibb International, and various senior executive
positions at Abbott Laboratories and Pfizer, Inc. Mr. Baker currently is a member of the Board of Directors of Progenics Pharmaceuticals, Inc.
Michael S. Brown, MD |
Professor of Molecular Genetics, Department of
Molecular Genetics, The University of Texas Southwestern Medical Center at Dallas |
Michael S. Brown, MD, has been a Director of the Company since June 1991. Dr. Brown is Professor of Medicine and Genetics and the Director of the Center for
Genetic Diseases at the University of Texas Southwestern Medical Center at Dallas, a position he has held since 1985. His scientific contributions in cholesterol
and lipid metabolism were made in collaboration with Dr. Joseph L. Goldstein. Drs. Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine
in 1985. Dr. Brown is a member of the Board of Directors of Pfizer, Inc.
Alfred G. Gilman, MD, PhD |
Dean, The University of Texas Southwestern Medical Center at Dallas |
Alfred G. Gilman, MD, PhD, a co-founder of the Company, has been a Director of the Company since July 1990. Dr. Gilman has served as Dean of the University of
Texas Southwestern Medical School since 2005 and has held the Raymond and Ellen Willie Distinguished Chair in Molecular Neuropharmacology at the University of Texas
Southwestern Medical School since 1987. Dr. Gilman is a member of the National Academy of Sciences and he received the Nobel Prize for Physiology or Medicine in
1994. Dr. Gilman is a member of the Board of Directors of Eli Lilly and Company.
Joseph L. Goldstein, MD |
Professor and Chairman, Department of Molecular Genetics,
The University of Texas Southwestern Medical Center at Dallas |
Joseph L. Goldstein, MD, has been a Director of the Company since June 1991. Dr. Goldstein has been Professor of Medicine and Genetics and Chairman of the Department
of Molecular Genetics at The University of Texas Southwestern Medical Center at Dallas since 1977. Dr. Goldstein is a member of the National Academy of Sciences. Drs. Goldstein
and Brown jointly received the Nobel Prize for Physiology or Medicine in 1985.
Arthur F. Ryan |
Chairman and Chief Executive Officer, Prudential Financial, Inc. |
Arthur F. Ryan has been a Director of the Company since January 2003. Mr. Ryan is the Chairman and Chief Executive Officer of Prudential Financial, Inc., one of the
largest diversified financial institutions in the world. Prior to joining Prudential in December 1994, Mr. Ryan served as President and Chief Operating Officer of
Chase Manhattan Bank since 1990. Mr. Ryan ran Chase's worldwide retail bank between 1984 and 1990.
Eric M. Shooter, PhD |
Professor of Neurobiology, Department of Neurobiology, Stanford University School of Medicine |
Eric M. Shooter, PhD, a co-founder of the Company, has been a Director since 1988. Dr. Shooter has been a Professor at Stanford University School of Medicine since 1968
and is now a Professor Emeritus. He was the founding Chairman of the Department of Neurobiology at Stanford University School of Medicine in 1975 and served as its
Chairman until 1987. Dr. Shooter is a Fellow of the Royal Society of England and a member of the National Academy of Sciences.
George L. Sing |
Managing Director, Lancet Capital |
George L. Sing has been a Director of the Company since January 1988. Since 1998, he has been a Managing Director of Lancet Capital, a venture capital investment firm
in the healthcare field.
